Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsViva Health Leuprolide Suspension Coverage | OpenP…
    Ask Trek AI about this page
    CurrentViva HealthPolicy IC-0080

    Leuprolide Suspension (coverage criteria)

    Customize your policy alerts

    Sign up for Viva Health Policy IC-0080 alerts

    Get alerted when Policy IC-0080 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Viva Health prior authorization, dosing limits, and medical necessity criteria for leuprolide suspension formulations across multiple indications including CPP, cancer, endometriosis, fibroids, gender dysphoria, fertility preservation, and HCT-related bleeding.

    Policy Summary
    PayerViva Health
    PolicyLeuprolide Suspension (coverage criteria)
    Policy CodePolicy IC-0080
    Change TypeMinor or no material change
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization and document indication-specific diagnostic confirmation and required prior trials or monitoring to support initial approval and renewals.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsinitial PA duration
    6 monthsendometriosis / HCT
    monthly/3mo/6modose schedules
    J1950primary HCPCS

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Appendix A present
    CMS note

    Coverage Criteria — Indications and Approvals

    Central Precocious Puberty (CPP) — Initial Approval

    Covered when ALL of the following are met

    CPP initial criteria: Member is less than 13 years of age; onset of secondary sexual characteristics earlier than age 8 for females and 9 for males associated with pubertal pituitary gonadotropin activation; diagnosis is confirmed by pubertal gonadal sex steroid levels and a pubertal luteinizing hormone (LH) response to stimulation by native GnRH; bone age advanced >2 standard deviations beyond chronological age; tumor has been ruled out by appropriate imaging and laboratory testing (e.g., brain imaging, pelvic/testicular/adrenal ultrasound, hCG levels); will not be used in combination with growth hormone; AND patient has a documented contraindication, intolerance, or failure to Leupron Depot‑Ped, Supprelin LA, AND Triptodur prior to consideration of Fensolvi.

    Includes requirement for prior trial/failure of listed pediatric alternatives.

    Endometriosis — Initial Approval

    Covered when ALL of the following are met

    Endometriosis: Member's diagnosis has been confirmed by a clinical workup/evaluation (not presumptive treatment); initial authorization is limited to 6 months (180 days).

    Extended retreatment criteria and bone density/add‑back requirements are in the renewal/continuation section.

    Uterine Leiomyomata (fibroids) — Initial Approval

    Covered when ALL of the following are met

    Uterine leiomyomata (fibroids): Member's diagnosis has been confirmed by a clinical workup/evaluation; AND member is receiving iron therapy; initial authorization validity is 3 months (90 days) and renewals are NOT allowed.

    Use beyond the initial period without documented evaluation and iron therapy does not meet criteria.

    Breast Cancer — Initial Approval

    Covered when ALL of the following are met

    Breast cancer scenarios: Either: member is a premenopausal woman with hormone receptor‑positive disease AND used in combination with adjuvant endocrine therapy OR used in combination with endocrine therapy for recurrent unresectable or stage IV (M1) disease; OR member is a male (sex assigned at birth) AND used in combination with aromatase inhibitor therapy.

    Relevant HCPCS include J9217, J1950, and J1954 as referenced.

    Ovarian/Fallopian Tube/Primary Peritoneal Cancer — Initial Approval

    Covered when ONE of the following indication-specific sets is met

    Ovarian and related cancers: Use as a single agent for: stage II–IV granulosa cell tumors with relapsed disease; OR specified epithelial/mucinous/clear cell/carcinosarcoma/grade‑1 endometrioid tumors with persistent or recurrent disease (excluding immediate biochemical relapse); OR low‑grade serous carcinoma with disease recurrence and prior aromatase inhibitor therapy.

    HCPCS referenced include J9217, J1954, and J1950.

    Prostate Cancer — Initial Approval

    Covered when ALL of the following are met

    Prostate cancer: Patient must have a documented contraindication, intolerance, or failure to Camcevi, Eligard, AND Firmagon prior to consideration of Lupron; AND renewal requests must demonstrate disease response and absence of unacceptable toxicity per general renewal criteria.

    HCPCS referenced include J9217, J1952, J1954, and J9003; see renewal criteria for response requirements.

    Head and Neck Cancer — Initial Approval

    Covered when ALL of the following are met

    Head and neck (salivary gland) tumors: Member has salivary gland tumors; AND therapy is used as a single agent OR in combination with abiraterone and prednisone; AND member has androgen‑receptor positive recurrent disease with distant metastases, unresectable locoregional recurrence with prior radiation therapy, or unresectable second primary with prior radiation therapy; AND renewal must show disease response and absence of unacceptable toxicity.

    HCPCS referenced include J9217, J1950, J1952, and J9003.

    Prevention/Management of Menstrual Bleeding Associated with HCT — Initial Approval

    Covered when ANY of the following are met

    HCT bleeding prevention/management: Member is premenopausal AND will receive myeloablative conditioning cytotoxic chemotherapy; OR member has menorrhagia due to thrombocytopenia related to delayed platelet engraftment after HCT.

    Initial authorization provided for 6 months (180 days) and is NOT renewable.

    Fertility Preservation While Receiving Chemotherapy — Initial Approval

    Covered when ALL of the following are met

    Fertility preservation: Member is premenopausal; AND member is receiving cytotoxic chemotherapy with potential to cause ovarian damage/toxicity; AND member has failed or is not a candidate for other fertility preservation methods (e.g., cryopreservation); AND for HCT‑associated conditioning, therapy is started 4–5 weeks prior to conditioning chemotherapy and continued until platelets >50,000 post‑HCT as required.

    Authorization may be renewed every 12 months while the member is receiving concomitant cytotoxic chemotherapy.

    Gender Dysphoria — Initial Approval

    Covered when ALL of the following are met

    Gender dysphoria initial criteria: Member has experienced puberty to at least Tanner stage 2 (if <18 years); AND member has a diagnosis of gender dysphoria confirmed by a qualified mental health professional OR by DSM‑5‑TR criteria; AND a qualified mental health professional has documented that the member demonstrates a long‑lasting/intense pattern of gender dysphoria, that dysphoria worsened with puberty, that coexisting issues have been addressed and the member has capacity to consent; AND the member was informed of effects/side effects including potential fertility loss and options to preserve fertility and has provided informed consent (with parental/guardian consent as required); AND for adolescents a pediatric endocrinologist or clinician experienced in pubertal assessment has confirmed agreement in indication for treatment and absence of medical contraindications.

    Multiple HCPCS may apply (J1950, J1951, J1952, J1954, J9003, J9217).

    General Renewal Criteria

    Renewal of prior authorization is allowed when ALL of the following are met:

    General renewal requirements: Member continues to meet the indication‑specific relevant criteria identified in section III; AND duration of authorization has not been exceeded per Section I; AND disease response with treatment is demonstrated (stabilization or decrease in tumor size/spread when applicable); AND absence of unacceptable toxicity from the drug (examples provided in policy such as tumor flare, metabolic syndrome, cardiovascular events, QT/QTc prolongation, convulsions, severe cutaneous adverse reactions, hypersensitivity).

    Applies to cancer and other indications where disease response is measurable.

    Central Precocious Puberty (CPP) — Renewal criteria

    Covered when ALL of the following are met:

    CPP renewal/continuation: Member remains less than 13 years of age; AND demonstrates disease response as indicated by lack of progression or stabilization of secondary sexual characteristics, decreased height velocity, decreased BA:CA ratio, and improvement in final height prediction; AND absence of unacceptable toxicity from the drug; AND therapy is not used in combination with growth hormone.

    Specific to J1950 and J1951 billing codes referenced.

    Gender Dysphoria — Renewal criteria

    Covered when ALL of the following are met:

    Gender dysphoria renewal/continuation: Member has shown a beneficial response to treatment as evidenced by routine monitoring of clinical pubertal development (if applicable) and relevant laboratory parameters; AND absence of unacceptable toxicity from the drug (examples listed in policy).

    DSM‑5‑TR diagnostic criteria and qualified mental health professional requirements referenced for initial diagnosis.

    Endometriosis — Renewal criteria

    Covered when ALL of the following are met:

    Endometriosis extended therapy/retreatment: Member has not received a total of 12 months of GnRH‑agonist therapy; AND member continues to have symptoms or symptoms recur after an initial 6‑month course; AND bone density assessment prior to retreatment; AND extended therapy will be used in combination with norethindrone add‑back therapy; AND absence of unacceptable toxicity.

    Applies to J1950; initial authorization is 6 months and may be renewed one time only for 6 months to a cumulative 12 months.

    Fertility Preservation While Receiving Chemotherapy — Renewal criteria

    Covered when ALL of the following are met:

    Fertility preservation during chemotherapy renewal: Member is still receiving cytotoxic chemotherapy; AND therapy was started per guidance (e.g., 4–5 weeks prior to conditioning chemotherapy for HCT when applicable) and continued as required (e.g., until platelets >50,000 post‑HCT); AND absence of unacceptable toxicity from the drug.

    Authorization may be renewed every 12 months while member is receiving concomitant cytotoxic chemotherapy; dosing guidance (e.g., 3.75 mg monthly) referenced.

    Per the policy, renewals are not allowed for therapy used to prevent or manage menstrual bleeding associated with hematopoietic stem cell transplant (HCT) and for treatment of uterine leiomyomata (fibroids). Initial prior authorization durations are specified (HCT-related bleeding: 6 months (180 days); uterine leiomyomata: 3 months (90 days)) and renewal is explicitly prohibited for these indications.

    The policy states that therapy for central precocious puberty (CPP) will not be used in combination with growth hormone. This restriction applies both for initial therapy and for continuation/renewal decisions and is listed among CPP-specific continuation criteria.

    The policy instructs that concurrent use of fractional doses or combining doses of this or any depot formulation is not permitted. Administration notes specify that several depot and suspension products must be given by a healthcare provider and caution against mixing fractional or combined depot doses.

    Medicare rules may override or supplement the policy: compliance with CMS guidance is required where applicable. Specifically, the policy directs readers to the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50, and notes that National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) may apply

    The policy documents that ICD-10 code F64.9 (Gender identity disorder, unspecified) is listed as Discontinued effective 10/1/26 and indicates the updated code F64.A (gender identity disorder, in remission) as effective 10/1/26 where applicable.

    Use of leuprolide for uterine leiomyomata (fibroids) is covered only when the member’s diagnosis is confirmed by evaluation and the member is receiving iron therapy. Initial prior authorization for this indication is provided for 3 months (90 days), and the policy specifies that renewals for uterine leiomyomata are not allowed.

    For endometriosis, retreatment beyond the initial course requires additional safeguards: retreatment is allowed only when the member has not exceeded a total of 12 months of GnRH-agonist therapy, continues to have symptoms after the initial 6‑month course, and has a documented bone density assessment prior to retreatment. Extended therapy must be used in combination with norethindrone add-back therapy, and absence of unacceptable toxicity must be documented.

    Initial Therapy Criteria and Dosing

    CPP initial therapy — Initial therapy requires diagnostic confirmation and prior failure/intolerance of listed pediatric agents

    Initial therapy for CPP requires diagnostic confirmation and prior failure/intolerance of listed pediatric agents

    CPP initial therapy specifics: See CPP initial approval criteria: age <13, early secondary sexual characteristics as defined, diagnostic confirmation (pubertal steroid levels and LH response to stimulation), bone age advancement >2 SD, tumor exclusion, will not be used with growth hormone, AND documented contraindication/intolerance/failure to Leupron Depot‑Ped, Supprelin LA, AND Triptodur prior to consideration of Fensolvi.

    References HCPCS J1950 and J1951.

    Initial Therapy / Dosing Examples

    Dosing and administration per indication and product (examples listed in document)

    Selected dosing examples: Examples per product and indication: Endometriosis/uterine neoplasms — 3.75 mg IM monthly or 11.25 mg IM every 3 months; CPP — Lupron Depot‑Ped and Fensolvi schedules including 45 mg SC q6 months or weight‑based monthly pediatric dosing (7.5–15 mg monthly) and 11.25/30 mg q3 months; Breast/Ovarian cancer — 3.75–7.5 mg monthly or 11.25–22.5 mg q3 months; Prostate cancer — depot schedules including 7.5 mg q4 weeks, 22.5 mg q12 weeks, 30 mg q16 weeks, 45 mg q24 weeks; Fertility preservation/HCT — start 4–5 weeks prior to conditioning chemo and 3.75 mg IM monthly.

    Renewal and Continuation Rules

    Renewal/Continuation rules

    Renewal rules vary by indication

    Renewal/Continuation rules: Renewals may be every 12 months thereafter unless otherwise specified; Endometriosis may be renewed one time only for 6 months (to a cumulative 12 months); Fertility preservation during chemotherapy may be renewed every 12 months while receiving concomitant cytotoxic chemotherapy; Prevention/management of HCT‑related bleeding and uterine leiomyomata may NOT be renewed.

    Refer to Section I for specific authorization lengths.

    Continuation Therapy — Requires demonstration of ongoing benefit and absence of unacceptable toxicity; indication-specific measures apply

    Requires demonstration of ongoing benefit and absence of unacceptable toxicity; indication-specific measures apply

    Continuation general: Member continues to meet indication‑specific criteria; duration of authorization has not been exceeded; disease response or stabilization demonstrated (e.g., stabilization or decrease in tumor size/spread for cancers; stabilization/decrease in pubertal progression and improved height prediction for CPP); AND absence of unacceptable toxicity (examples listed in policy such as tumor flare, metabolic syndrome, cardiovascular events, QT/QTc prolongation, convulsions, severe cutaneous adverse reactions, hypersensitivity, significant bone mineral density loss).

    Billing Codes, Diagnosis Codes, and Quantity Limits

    Primary HCPCS (examples)HCPCS
    J1950Leuprolide acetate, per 3.75 mg
    Additional HCPCSHCPCS
    J1951Leuprolide acetate, per 7.5 mg
    J1952Leuprolide acetate, per 22.5 mg
    Additional HCPCSHCPCS
    J1954Leuprolide acetate, per 30 mg
    Oncology HCPCSHCPCS
    J9217Leuprolide acetate, 7.5 mg
    Oncology HCPCSHCPCS
    J9003Leuprolide acetate, (Lutrate Depot) 21 mg (policy lists J9003 tied to prostate/head & neck/gender dysphoria)
    Billing HCPCS CodesHCPCS
    J1950Injection, leuprolide acetate (for depot suspension), per 3.75 mg
    J9217Leuprolide acetate (for depot suspension), 7.5 mg
    J1951HCPCS J1951 (Camcevi association)
    J1952HCPCS J1952 (Camcevi ETM association)
    J1954HCPCS J1954 (Leuprolide Acetate Depot - Cipla association)
    J9003HCPCS J9003 (Lutrate Depot - Avyxa association)
    NDCs (examples)NDC
    00074-3641-xxLupron Depot 1-Month NDC example
    00074-3663-xxLupron Depot 3-Month NDC example
    62935-0753-xxEligard NDC example
    85043-0075-xxVabrinty NDC example
    62935-0153-xxFensolvi NDC example
    62935-0163-xxCamcevi NDC example
    69448-0014-xxCamcevi / Lutrate Depot NDC example
    83831-0134-xxLeuprolide Acetate Depot (Cipla) NDC example
    Covered HCPCSHCPCSCovered
    J1950Leuprolide acetate for depot suspension (billing code header shown in document)
    Covered ICD-10 Diagnosis Codes (partial list shown)ICD-10Covered
    C06.9Malignant neoplasm of mouth, unspecified
    C07Malignant neoplasm of parotid gland
    C08.0Malignant neoplasm of submandibular gland
    C08.1Malignant neoplasm of sublingual gland
    C08.9Malignant neoplasm of major salivary gland, unspecified
    C48.1Malignant neoplasm of specified parts of peritoneum
    C48.2Malignant neoplasm of peritoneum, unspecified
    C48.8Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum
    C50.011Malignant neoplasm of nipple and areola, right female breast
    C50.012Malignant neoplasm of nipple and areola, left female breast
    1–10 of 109
    1/11
    HCPCS codes shown in section startHCPCS
    J1950HCPCS code listed in this policy segment
    Additional HCPCS (J9217) and associated ICD-10 listsHCPCS
    J9217HCPCS J9217 listed in this policy segment
    HCPCS J1951HCPCS
    J1951HCPCS J1951 listed in this policy segment
    HCPCS J1952HCPCS
    J1952HCPCS J1952 listed in this policy segment
    HCPCS J1954 and associated ICD-10 listsHCPCS
    J1954HCPCS J1954 listed in this policy segment
    HCPCS J9003HCPCS
    J9003HCPCS J9003 listed in this policy segment
    Endometriosis ICD-10 codes (partial list shown)ICD-10Covered
    N80.369Superficial endometriosis of the pelvic brim, unspecified side
    N80.371Deep endometriosis of the right pelvic brim
    N80.372Deep endometriosis of the left pelvic brim
    N80.373Deep endometriosis of bilateral pelvic brim
    N80.379Deep endometriosis of the pelvic brim, unspecified side
    N80.381Endometriosis of the right pelvic brim, unspecified depth
    N80.382Endometriosis of the left pelvic brim, unspecified depth
    N80.383Endometriosis of bilateral pelvic brim, unspecified depth
    N80.389Endometriosis of the pelvic brim, unspecified side, unspecified depth
    N80.3A1Superficial endometriosis of the right uterosacral ligament
    1–10 of 17
    1/2
    Covered HCPCS/J codes referencedHCPCS
    J9003
    J1950
    J9217
    J1952
    J1954
    Listed ICD-10 diagnosis codesICD-10
    C06.9Malignant neoplasm of mouth, unspecified
    C07Malignant neoplasm of parotid gland
    C08.0Malignant neoplasm of submandibular gland
    C08.1Malignant neoplasm of sublingual gland
    C08.9Malignant neoplasm of major salivary gland, unspecified
    C61Malignant neoplasm of prostate
    D37.031Neoplasm of uncertain behavior of the sublingual salivary glands
    D37.032Neoplasm of uncertain behavior of the submandibular salivary glands
    D37.039Neoplasm of uncertain behavior of the major salivary glands, unspecified
    F64.0Transsexualism
    1–10 of 16
    1/2
    Per-indication unit limits — J1950
    J1950 per-indication limitsHead & neck cancer, uterine neoplasms, endometriosis, uterine leiomyomata: 3 billable units every 84 days; Breast/ovarian/peritoneal cancer: 6 billable units every 84 days; CPP and gender dysphoria: 24 billable units every 168 days; HCT-related bleeding and fertility preservation during chemotherapy: 1 billable unit every 28 days
    ScopeLimits apply to HCPCS J1950 (leuprolide acetate, per 3.75 mg) as listed in dosing limits
    Reference section

    Quantity Limits and Product-specific Schedules

    J1950 (per listed indication) — per-indication unit limits
    Examples of J1950 limits by indicationEndometriosis/uterine neoplasms/fibroids: 3 units every 84 days; Breast/Ovarian/Primary peritoneal cancer: 6 units every 84 days; CPP/Gender dysphoria: 24 units every 168 days; HCT-related bleeding and fertility preservation: 1 unit every 28 days
    Dosing cross-referenceDosage/administration section lists typical product dosing (e.g., 3.75 mg monthly, 11.25 mg q3 months) corresponding to billed units
    Billing unit definitionLimits expressed as billable HCPCS units tied to J1950 per 'II. Dosing Limits'
    J1951 / J1952 — quantity limits
    J1951 limit (primary uses)180 billable units every 168 days for Central Precocious Puberty (CPP) and Gender Dysphoria
    J1952 limit (primary uses)

    Authorization, Documentation, and Billing — Provider Actions

    Prior Authorization

    Prior authorization duration

    Initial prior authorization is valid for 12 months (365 days) by default; exceptions: endometriosis and prevention/management of menstrual bleeding associated with HCT are initially authorized for 6 months (180 days), and uterine leiomyomata (fibroids) is initially authorized for 3 months (90 days). Renewals are generally every 12 months (365 days) unless an indication-specific limit applies (endometriosis may be renewed one time only for 6 months; HCT-related bleeding and uterine fibroids may NOT be renewed; fertility preservation may be renewed every 12 months while receiving cytotoxic chemotherapy).

    • Initial: 12 months (365 days) standard
    • Endometriosis: initial 6 months (180 days)
    • HCT bleeding prevention/management: initial 6 months (180 days)
    • Uterine fibroids: initial 3 months (90 days)
    • Renewal: generally every 12 months; endometriosis renew once for 6 months; HCT and fibroids not renewable; fertility preservation renewable yearly while on chemo
    Prior Authorization

    Prior authorization must meet indication-specific criteria for renewal

    Step Therapy and Prior Treatment Requirements

    IndicationStep requirementRequired documentation / failure criteria
    Central Precocious Puberty (CPP)Prior trial, intolerance, or failure of Leuprolide Depot‑Ped, Supprelin LA, AND Triptodur required before consideration of alternative productDocument contraindication, intolerance, or treatment failure to the listed pediatric comparator products; diagnostic confirmation requirements (age <13, early secondary sexual characteristics, pubertal gonadal sex steroid levels, pubertal LH response to stimulation, bone age >2 SD, tumor ruled out) must be met
    Prostate cancerPrior trial, intolerance, or failure of Camcevi, Eligard, AND Firmagon required before consideration of LupronDocument contraindication, intolerance, or failure to the listed comparator products
    ScenarioRetreatment / extension requirementRequired assessments / concomitant therapy
    Endometriosis — retreatment beyond initial 6 months up to cumulative 12 monthsMember must not have received a total of 12 months of GnRH‑agonist therapy; retreatment allowable when symptoms persist or recur after initial 6‑month courseBone density assessment prior to retreatment; extended therapy must be used in combination with norethindrone add‑back therapy; document absence of unacceptable toxicity

    Site of Care and Administration Requirements

    Billing Rule

    Administration site and provider‑administered products

    Leuprolide products such as Camcevi, Camcevi ETM, Eligard, Vabrinty, Fensolvi, and Lupron Depot-Ped must be administered by a healthcare provider; administration routes vary by product (IM or SQ) and site‑of‑care requirements are noted in the dosing/administration section.

    • Administered by a healthcare provider: Camcevi, Camcevi ETM, Eligard, Vabrinty, Fensolvi, Lupron Depot-Ped
    • Routes: IM for Lupron Depot/Lutrate/Leuprolide Acetate Depot; SQ for Eligard, Vabrinty, Fensolvi, Camcevi, Camcevi ETM
    Billing Rule

    Medicare Part B site‑of‑care and billing rules may apply

    Where Medicare Part B applies, site-of-care and billing rules for office, infusion center, or hospital outpatient settings follow NCD/LCD/LCA jurisdiction guidance and applicable Medicare Part B contractor policies.

    Definitions and Terminology

    Qualified mental health professional — definition
    Minimum qualificationLicensed by statutory body and hold at minimum a master's degree or equivalent training in a clinical field relevant to this role
    Clinical competenciesAble to identify co-existing mental health or psychosocial concerns and distinguish these from gender dysphoria; able to assess capacity to consent
    Diagnostic competenceFor jurisdictions requiring diagnostic coding, competent in using the WHO ICD; engages in continuing education in gender dysphoria care
    DSM-5-TR gender dysphoria — summary
    Core DSM-5-TR definitionMarked incongruence between experienced/expressed gender and natal gender of at least 6 months' duration, manifested by at least two specified features (e.g., desire to be rid of sex characteristics, desire to be treated as other gender)
    Associated requirement

    Background and Clinical Context

    Leuprolide (GnRH-agonist) is used across pediatric and adult indications to suppress gonadal function. Indications in the policy include central precocious puberty (CPP), hormone-sensitive cancers (breast, ovarian, prostate), endometriosis, uterine leiomyomata (fibroids), gender dysphoria, prevention/management of HCT‑associated menstrual bleeding, and fertility preservation during cytotoxic chemotherapy. The document references diagnostic confirmation requirements, specialist involvement where appropriate (e.g., pediatric endocrinologist, qualified mental health professional), product-specific administration routes (IM or SQ), and dosing/authorization durations that vary by indication.

    Policy Revision History

    2026-07-01policy_reviewLatest

    Policy IC-0080 (Leuprolide Suspension) last reviewed and effective date recorded as 2026-07-01; Medicare/Part B guidance and CMS NCD/LCD/LCA applicability noted in Appendix 2.

    Policy Summary
    PayerViva Health
    PolicyLeuprolide Suspension (coverage criteria)
    Policy CodePolicy IC-0080
    Change TypeMinor or no material change
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization and document indication-specific diagnostic confirmation and required prior trials or monitoring to support initial approval and renewals.
    SourceLink
    On This Page
    Coverage Criteria — Indications and ApprovalsInitial Therapy Criteria and DosingRenewal and Continuation RulesBilling Codes, Diagnosis Codes, and Quantity LimitsQuantity Limits and Product-specific SchedulesAuthorization, Documentation, and Billing — Provider ActionsStep Therapy and Prior Treatment RequirementsSite of Care and Administration RequirementsDefinitions and TerminologyBackground and Clinical ContextPolicy Revision History

    See dosing section for full per‑product specifics.

    Applies across cancer, CPP, gender dysphoria, endometriosis, and fertility preservation indications.

    See 'II. Dosing Limits' for full per-indication unit breakdown
    NQTL considerations
    NQTL rationalePrior authorization applied as a utilization management NQTL primarily because of drug cost (Appendix A conclusion: 'Cost of drug, 1 = Yes: Consider for PA')
    Other NQTL factors consideredSafety/efficacy and potential for misuse/abuse were assessed and not prioritized for PA (Appendix A)
    ApplicationPA methods used comparably for MH/SUD and M/S drugs per the checklist description
    42 billable units every 168 days for Prostate Cancer, Head & Neck Cancer, and Gender Dysphoria
    Coding noteJ1951/J1952 correspond to higher-strength depot products with indication-specific schedules listed in dosage/administration
    J1954 — quantity limits
    J1954 limit3 billable units every 84 days for listed cancer and gender dysphoria indications
    Associated indicationsBreast, ovarian/fallopian tube/primary peritoneal cancer, prostate cancer, and gender dysphoria
    Dosing linkSee Dosage/Administration for per-product schedules that correspond to billed units
    J9217 — quantity limits
    J9217 limits3 billable units every 84 days for several cancers (breast, head & neck, ovarian/fallopian tube/primary peritoneal); and 12 billable units every 336 days for prostate cancer and gender dysphoria
    Oncology associationJ9217 is listed with multiple malignant neoplasm ICD-10 codes in the policy
    Dosing cross-referenceRefer to Dosage/Administration for depot schedules tied to J9217 billing
    J9003 — quantity limits
    J9003 limit21 billable units every 84 days for prostate cancer, head & neck cancer, and gender dysphoria
    Associated ICD-10sJ9003 is listed alongside multiple malignant neoplasm and gender identity ICD-10 codes in the coding tables
    Use noteLimits represent HCPCS billing units per dosing schedules described in Dosage/Administration
    Leuprolide depot products — product-specific dosing schedules
    Per-product schedulingLeuprolide depot products are dosed per specific product schedules (examples: 3.75 mg monthly; 7.5 mg monthly; 11.25 mg q3 months; 22.5 mg q12 weeks; 30 mg q16 weeks; 45 mg q24 weeks) as listed in the Dosage/Administration section
    Examples by productFensolvi, Lupron Depot-Ped, Camcevi, Camcevi ETM, Eligard, Vabrinty, Lutrate Depot, Leuprolide Acetate Depot dosing examples appear in the Dosage/Administration tables
    Relation to billing unitsProduct-specific mg schedules map to billed HCPCS units (see corresponding J-code entries and dosing limits)

    Prior authorization must be obtained prior to therapy and may be renewed only when the indication-specific criteria in Section III are still met and treatment duration limits from Section I have not been exceeded; renewal requires documentation of disease response and absence of unacceptable toxicity.

    • PA required before treatment; renew only if indication criteria met
    • Renewal contingent on duration limits not exceeded (see Length of Authorization)
    • Documentation must show disease response and no unacceptable toxicity
    Prior Authorization

    Prior authorization applied to J1950 (cost-based NQTL)

    Prior authorization is applied to HCPCS J1950 as a utilization management NQTL because cost of the drug was identified as a factor in the NQTL checklist.

    • J1950 specifically listed in NQTL considerations
    • Cost of drug noted as rationale to consider PA
    Prior Authorization

    J1950 listed with diagnosis-specific PA rules

    HCPCS J1950 appears in the policy with multiple ICD-10 diagnosis codes (including numerous endometriosis codes) and is subject to the policy's prior authorization rules; see the J1950 listings and indication sections for specific PA requirements and ICD-10 support.

    • J1950 listed with extensive ICD-10 codes for endometriosis and oncology
    • PA requirements for J1950 are governed by the policy's prior authorization sections
    Billing Rule

    Reference correct HCPCS/J-code and supporting ICD-10 when requesting PA

    When requesting coverage or billing for leuprolide J‑codes (e.g., J1950, J1951, J1952, J1954, J9003, J9217), providers must reference the listed HCPCS/J-codes with the appropriate supporting ICD-10 diagnosis codes; Medicare Part B coding/coverage rules (NCD/LCD/LCA) may apply depending on jurisdiction.

    • Use the HCPCS/J-code that matches the product and indication
    • Include the supporting ICD-10 diagnosis code from the policy lists
    • Follow applicable Medicare Part B NCD/LCD/LCA rules in your jurisdiction
    Step Therapy

    Required trial of listed alternatives before coverage

    For CPP and for prostate cancer, the policy requires documentation of prior intolerance, contraindication, or treatment failure to the specified alternative agents before coverage will be considered for the requested leuprolide product.

    • CPP: must show contraindication, intolerance, or failure to Leupron Depot‑Ped, Supprelin LA, AND Triptodur before Fensolvi consideration
    • Prostate cancer: must show contraindication, intolerance, or failure to Camcevi, Eligard, AND Firmagon before Lupron consideration
    Step Therapy

    Endometriosis retreatment requires bone density check and add-back therapy

    For endometriosis retreatment or extended GnRH-agonist therapy beyond the initial 6-month course, providers must document a bone density assessment prior to retreatment and plan to use norethindrone add-back therapy for the extended course.

    • Patient has not received a total of 12 months of GnRH-agonist therapy
    • Bone density assessment required before retreatment
    • Extended therapy must be given with norethindrone add-back therapy
    Note

    NQTL checklist: PA considered for cost; step therapy not prioritized

    The NQTL factor checklist documents that step therapy was not prioritized for safety or misuse reasons, but prior authorization was considered primarily because of drug cost.

    • Checklist: indication considered = yes; safety/efficacy and misuse not prioritized; cost = yes (consider PA)
    Denial Risk

    Denial risk if CPP diagnostic confirmation is not documented

    Failure to provide the required CPP diagnostic documentation (pubertal steroid levels, LH stimulation test results, bone age assessment >2 SD, and tumor exclusion testing) may result in denial of the request.

    • Missing LH stimulation test or pubertal steroid levels risks denial
    • Missing bone age >2 SD or absence of tumor exclusion testing risks denial
    Note
    Documentation Required

    Provide documented diagnostic workup to confirm listed diagnoses

    For indications that require diagnosis confirmation (for example, endometriosis and uterine leiomyomata), providers must submit objective diagnostic workup or evaluation documentation rather than presumptive treatment notes.

    • Endometriosis: diagnosis confirmed by workup/evaluation (not presumptive)
    • Uterine fibroids: diagnosis confirmed by workup/evaluation and member must be receiving iron therapy
    Documentation Required

    Evidence required for renewal: document clinical benefit and safety

    For renewal requests, submit objective evidence of beneficial response to treatment (examples include monitoring of pubertal development and laboratory parameters for gender dysphoria; stabilization or decrease in tumor size/spread for oncology; for CPP, decrease in height velocity, decreased BA:CA ratio, and improved final height prediction) and documentation of absence of unacceptable toxicity.

    • Document clinical monitoring results demonstrating benefit (per-indication examples in continuation criteria)
    • State absence of unacceptable toxicity as listed in renewal criteria
    Note
    Documentation Required

    Follow CMS/Medicare Part B coverage and documentation guidance when applicable

    Medicare Part B coverage and documentation requirements may apply; providers should follow the Medicare Benefit Policy Manual Chapter 15 §50 and search the CMS Medicare Coverage Database for applicable NCDs, LCDs, or LCAs that may affect Part B outpatient drug coverage and billing.

    • Follow Medicare Benefit Policy Manual (Pub. 100-2) Chapter 15 §50 for Part B outpatient drugs
    • Search CMS Medicare Coverage Database for NCD/LCD/LCA documents: https://www.cms.gov/medicare-coverage-database/search.aspx
    • Compliance with applicable NCDs/LCDs/LCAs is required where applicable
    Billing Rule

    Use ICD-10 diagnosis codes from the policy to support medical necessity

    Diagnosis code(s) submitted to support medical necessity must match the ICD-10 codes listed in the policy (examples shown include C06.9, C07, C61, F64.x series, Z85.46, and numerous N80.* endometriosis codes) for the indicated use.

    • Use the ICD-10 diagnosis codes listed in the policy that correspond to the indication (e.g., N80.* for endometriosis)
    • Ensure submitted diagnosis matches policy-supported codes for the HCPCS/J-code billed
    Documentation Required

    Submit CPP diagnostic confirmation (steroids, LH stimulation, bone age, tumor exclusion)

    Documentation to support CPP must include diagnostic confirmation such as pubertal gonadal sex steroid levels, a pubertal LH response to stimulation by native GnRH (LH stimulation test), bone age advanced >2 SD beyond chronological age, and evidence that tumor has been ruled out (imaging and labs).

    • Pubertal gonadal sex steroid levels and pubertal LH response to native GnRH stimulation
    • Bone age >2 standard deviations beyond chronological age
    • Imaging/labs to rule out intracranial or steroid-secreting tumors (brain imaging, pelvic/testicular/adrenal ultrasound, hCG)
    Denial Risk

    Renewal may be denied for exceeded duration or unacceptable toxicity

    Renewals may be denied if the duration of the authorization has been exceeded or if the member has unacceptable toxicity from the drug (examples include tumor flare, metabolic syndrome, cardiovascular events, QT/QTc prolongation, convulsions, severe cutaneous adverse reactions, hypersensitivity, significant loss of bone mineral density, or new/worsening psychiatric symptoms).

    • Denial triggers: authorization duration exceeded
    • Denial triggers: presence of listed unacceptable toxicities (examples provided in renewal/continuation criteria)
    Prior Authorization

    Expect prior authorization because cost was identified in NQTL checklist

    Prior authorization may be considered for this drug group due to cost, per the NQTL factor checklist; providers should anticipate PA requirements when prescribing leuprolide depot/suspension products.

    • NQTL checklist identifies cost of drug as reason to consider PA
    • Expect prior authorization processes for leuprolide products
    Note

    Medicare coverage determinations may affect coverage and must be followed

    Medicare coverage determinations (NCDs/LCDs/LCAs) may supersede or apply to coverage decisions for Part B drugs; providers must comply with applicable Medicare coverage documents where relevant, and non‑Medicare determinations are also subject to CMS NCD/LCD/LCA guidance.

    • Medicare coverage may supersede non‑Medicare policy where applicable
    • Compliance with NCDs/LCDs/LCAs is required for Medicare Part B claims
    Note
    Note
    The condition must be associated with clinically significant distress or impairment in social, occupational, or other important areas of functioning
    Source referenceDSM-5-TR criteria summarized per policy '§ DSM-5-TR Criteria for Gender Dysphoria in Adolescents and Adults'
    Qualified mental health professional — alternate definition entries
    Licensed clinician requirementLicensed clinician with at minimum a master's degree (or equivalent) in a relevant clinical field able to assess co‑existing mental health conditions versus gender dysphoria
    Assessment capabilitiesMust be able to assess capacity to consent and identify psychosocial concerns; experienced in clinical aspects of gender dysphoria
    Professional developmentShould undergo continuing education in health care relating to gender dysphoria, incongruence, and diversity
    DSM-5-TR Criteria for Gender Dysphoria (adolescents/adults) — summary
    Adolescents/adults criteriaMarked incongruence for ≥6 months with at least two manifestations (e.g., desire to be rid of primary/secondary sex characteristics; strong desire to be treated as other gender), plus clinically significant distress/impairment
    Manifestations examplesIncludes desire for the other gender's sex characteristics, desire to be of the other gender, or conviction of typical feelings of the other gender
    Policy useDSM-5-TR criteria used as diagnostic standard for gender dysphoria approvals and continued therapy
    Central precocious puberty — definition and references
    Definition summaryCentral precocious puberty supported by referenced consensus statements and resources; diagnostic confirmation required for coverage (see CPP criteria)
    Reference examplesPolicy cites consensus statements and pediatric endocrinology literature to support CPP indications
    Clinical noteCPP criteria include pubertal LH response to stimulation, advanced bone age, and tumor exclusion per documentation guidance
    Endometriosis (ICD-10 N80.* series) — code group description
    ICD-10 groupEndometriosis codes: multiple N80.* codes enumerated for superficial and deep endometriosis across pelvic brim, uterosacral ligaments, pelvic peritoneum, rectovaginal septum, intestine, bladder, ureters, diaphragm and extra‑pelvic sites
    ExamplesIncluded codes: N80.369, N80.371–N80.383, N80.389, N80.3A1–N80.3B3, N80.3C1–N80.3C9, N80.391–N80.399, N80.40–N80.42, N80.50–N80.532, etc.
    Policy linkageThese ICD-10 codes are listed under J1950 in the policy coding tables for endometriosis indications
    Malignant neoplasms (ICD-10 C50*, C56*, C57*, etc.) — code group description
    Malignant neoplasm code groupPolicy lists numerous ICD-10 codes for malignant neoplasms (e.g., C06.9, C07, C50.* series, C54.*, C56.*, C57.*, C61) associated with leuprolide J‑codes
    Use across indicationsCodes support breast, ovarian/fallopian tube, primary peritoneal, prostate, head & neck, uterine, and other cancer indications tied to various J‑codes
    PlacementThese ICD-10 lists appear alongside J9217, J9003, and J1950 / other HCPCS in the coding tables
    HCPCS code listed in diagnosis/code table — J9003
    HCPCS referenceJ9003 is listed in the policy's diagnosis/code table and associated coding lists
    Associated indicationsJ9003 is tied to prostate, head & neck, and gender dysphoria indications in the coding section
    Cross-referenceSee J9003 quantity limits (21 units every 84 days) in the Quantity Limits section